People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nautilus Biotechnology, Inc. | — | Biotech | Series D+ | $303.3M | $6.0B | 2021 |
Melissa Epperly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Melissa Epperly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stuart Nagae | 1 | 9 |
| Vijay Pande | 1 | 9 |
| Matthew Posard | 1 | 4 |
| Michael Altman | 1 | 3 |
| MATTHEW S. MCILWAIN | 1 | 3 |
| Sujal Patel | 1 | 2 |
| Farzad Nazem | 1 | 2 |
| Matthew S. Murphy | 1 | 1 |
| Subra S. Sankar | 1 | 1 |
| Anna Mowry | 1 | 1 |
| Parag Mallick | 1 | 1 |
| Nicholas S. Nelson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.